Therapeutic targeting of RAS mutant cancers:
The KRAS oncogene is believed to be the most common single nucleotide variant oncogene in human cancer. Historically, efforts to target KRAS and the other RAS GTPases have struggled. More recently, efforts have focused on identifying and exploiting features unique to specific oncogenic mutations. Th...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Book |
| Language: | English |
| Published: |
Cambridge, United Kingdom ; New York, NY, USA
Cambridge University Press
2022
|
| Series: | Cambridge elements: elements in molecular oncology
|
| Subjects: | |
| Online Access: | Inhaltsverzeichnis |
| Summary: | The KRAS oncogene is believed to be the most common single nucleotide variant oncogene in human cancer. Historically, efforts to target KRAS and the other RAS GTPases have struggled. More recently, efforts have focused on identifying and exploiting features unique to specific oncogenic mutations. This has led to the first FDA approval for a RAS targeted therapy. This new agent is a covalent inhibitor that reacts with the cysteine residue created by a codon 12 glycine to cysteine (G12C) mutation within KRAS. Mutant-specific strategies may also exist for other KRAS single nucleotide variants, and recent studies provide examples and mechanisms |
| Physical Description: | 29 Seiten Illustrationen 152 x 228 mm |
| ISBN: | 9781009073646 1009073648 |
Staff View
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV049346286 | ||
| 003 | DE-604 | ||
| 005 | 20240212 | ||
| 007 | t | ||
| 008 | 230929s2022 a||| |||| 00||| eng d | ||
| 020 | |a 9781009073646 |c Broschur : EUR 20.95 |9 978-1-009-07364-6 | ||
| 020 | |a 1009073648 |9 1-009-07364-8 | ||
| 024 | 3 | |a 9781009073646 | |
| 035 | |a (OCoLC)1422396007 | ||
| 035 | |a (DE-599)BVBBV049346286 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 | ||
| 084 | |a XH 3500 |0 (DE-625)152892:12905 |2 rvk | ||
| 100 | 1 | |a Stites, Edward C. |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a Therapeutic targeting of RAS mutant cancers |c Edward C. Stites (Salk Institute for Biological Studies), Kendra Paskvan (Pacific Northwest University for Health Sciences), Shumei Kato (University of California San Diego) |
| 264 | 1 | |a Cambridge, United Kingdom ; New York, NY, USA |b Cambridge University Press |c 2022 | |
| 300 | |a 29 Seiten |b Illustrationen |c 152 x 228 mm | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 0 | |a Cambridge elements: elements in molecular oncology | |
| 520 | |a The KRAS oncogene is believed to be the most common single nucleotide variant oncogene in human cancer. Historically, efforts to target KRAS and the other RAS GTPases have struggled. More recently, efforts have focused on identifying and exploiting features unique to specific oncogenic mutations. This has led to the first FDA approval for a RAS targeted therapy. This new agent is a covalent inhibitor that reacts with the cysteine residue created by a codon 12 glycine to cysteine (G12C) mutation within KRAS. Mutant-specific strategies may also exist for other KRAS single nucleotide variants, and recent studies provide examples and mechanisms | ||
| 650 | 4 | |a Oncology / BIC2 | |
| 650 | 4 | |a Pathology / BIC2 | |
| 650 | 4 | |a Pharmacology / BIC2 | |
| 700 | 1 | |a Paskvan, Kendra |e Verfasser |4 aut | |
| 700 | 1 | |a Kato, Shumei |e Verfasser |4 aut | |
| 856 | 4 | 2 | |m Digitalisierung UB Regensburg - ADAM Catalogue Enrichment |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=034606755&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-034606755 | ||
Record in the Search Index
| _version_ | 1804185875789119488 |
|---|---|
| adam_text | Contents 1 Introduction 1 2 RAS Biology 1 3 Oncogenic RAS 4 4 RAS Targeting 5 5 Downstream Targeting 6 6 Upstream Targeting 7 7 Targeting Specific RAS Mutants 8 8 KRAS G12C Targeting 8 9 Direct Targeting of Other RAS Proteins 11 10 KRAS G12R Pancreatic Cancer 12 11 KRAS Gl 3D Colorectal Cancer 12 12 Summary 15 References 16
|
| adam_txt |
Contents 1 Introduction 1 2 RAS Biology 1 3 Oncogenic RAS 4 4 RAS Targeting 5 5 Downstream Targeting 6 6 Upstream Targeting 7 7 Targeting Specific RAS Mutants 8 8 KRAS G12C Targeting 8 9 Direct Targeting of Other RAS Proteins 11 10 KRAS G12R Pancreatic Cancer 12 11 KRAS Gl 3D Colorectal Cancer 12 12 Summary 15 References 16 |
| any_adam_object | 1 |
| any_adam_object_boolean | 1 |
| author | Stites, Edward C. Paskvan, Kendra Kato, Shumei |
| author_facet | Stites, Edward C. Paskvan, Kendra Kato, Shumei |
| author_role | aut aut aut |
| author_sort | Stites, Edward C. |
| author_variant | e c s ec ecs k p kp s k sk |
| building | Verbundindex |
| bvnumber | BV049346286 |
| classification_rvk | XH 3500 |
| ctrlnum | (OCoLC)1422396007 (DE-599)BVBBV049346286 |
| discipline | Medizin |
| discipline_str_mv | Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02299nam a2200385 c 4500</leader><controlfield tag="001">BV049346286</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20240212 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">230929s2022 a||| |||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781009073646</subfield><subfield code="c">Broschur : EUR 20.95</subfield><subfield code="9">978-1-009-07364-6</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1009073648</subfield><subfield code="9">1-009-07364-8</subfield></datafield><datafield tag="024" ind1="3" ind2=" "><subfield code="a">9781009073646</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1422396007</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV049346286</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XH 3500</subfield><subfield code="0">(DE-625)152892:12905</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Stites, Edward C.</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Therapeutic targeting of RAS mutant cancers</subfield><subfield code="c">Edward C. Stites (Salk Institute for Biological Studies), Kendra Paskvan (Pacific Northwest University for Health Sciences), Shumei Kato (University of California San Diego)</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Cambridge, United Kingdom ; New York, NY, USA</subfield><subfield code="b">Cambridge University Press</subfield><subfield code="c">2022</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">29 Seiten</subfield><subfield code="b">Illustrationen</subfield><subfield code="c">152 x 228 mm</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Cambridge elements: elements in molecular oncology</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The KRAS oncogene is believed to be the most common single nucleotide variant oncogene in human cancer. Historically, efforts to target KRAS and the other RAS GTPases have struggled. More recently, efforts have focused on identifying and exploiting features unique to specific oncogenic mutations. This has led to the first FDA approval for a RAS targeted therapy. This new agent is a covalent inhibitor that reacts with the cysteine residue created by a codon 12 glycine to cysteine (G12C) mutation within KRAS. Mutant-specific strategies may also exist for other KRAS single nucleotide variants, and recent studies provide examples and mechanisms</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oncology / BIC2</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pathology / BIC2</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmacology / BIC2</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Paskvan, Kendra</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kato, Shumei</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">Digitalisierung UB Regensburg - ADAM Catalogue Enrichment</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=034606755&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-034606755</subfield></datafield></record></collection> |
| id | DE-604.BV049346286 |
| illustrated | Illustrated |
| index_date | 2024-07-03T22:48:27Z |
| indexdate | 2024-07-10T10:02:11Z |
| institution | BVB |
| isbn | 9781009073646 1009073648 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-034606755 |
| oclc_num | 1422396007 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | 29 Seiten Illustrationen 152 x 228 mm |
| publishDate | 2022 |
| publishDateSearch | 2022 |
| publishDateSort | 2022 |
| publisher | Cambridge University Press |
| record_format | marc |
| series2 | Cambridge elements: elements in molecular oncology |
| spelling | Stites, Edward C. Verfasser aut Therapeutic targeting of RAS mutant cancers Edward C. Stites (Salk Institute for Biological Studies), Kendra Paskvan (Pacific Northwest University for Health Sciences), Shumei Kato (University of California San Diego) Cambridge, United Kingdom ; New York, NY, USA Cambridge University Press 2022 29 Seiten Illustrationen 152 x 228 mm txt rdacontent n rdamedia nc rdacarrier Cambridge elements: elements in molecular oncology The KRAS oncogene is believed to be the most common single nucleotide variant oncogene in human cancer. Historically, efforts to target KRAS and the other RAS GTPases have struggled. More recently, efforts have focused on identifying and exploiting features unique to specific oncogenic mutations. This has led to the first FDA approval for a RAS targeted therapy. This new agent is a covalent inhibitor that reacts with the cysteine residue created by a codon 12 glycine to cysteine (G12C) mutation within KRAS. Mutant-specific strategies may also exist for other KRAS single nucleotide variants, and recent studies provide examples and mechanisms Oncology / BIC2 Pathology / BIC2 Pharmacology / BIC2 Paskvan, Kendra Verfasser aut Kato, Shumei Verfasser aut Digitalisierung UB Regensburg - ADAM Catalogue Enrichment application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=034606755&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Stites, Edward C. Paskvan, Kendra Kato, Shumei Therapeutic targeting of RAS mutant cancers Oncology / BIC2 Pathology / BIC2 Pharmacology / BIC2 |
| title | Therapeutic targeting of RAS mutant cancers |
| title_auth | Therapeutic targeting of RAS mutant cancers |
| title_exact_search | Therapeutic targeting of RAS mutant cancers |
| title_exact_search_txtP | Therapeutic targeting of RAS mutant cancers |
| title_full | Therapeutic targeting of RAS mutant cancers Edward C. Stites (Salk Institute for Biological Studies), Kendra Paskvan (Pacific Northwest University for Health Sciences), Shumei Kato (University of California San Diego) |
| title_fullStr | Therapeutic targeting of RAS mutant cancers Edward C. Stites (Salk Institute for Biological Studies), Kendra Paskvan (Pacific Northwest University for Health Sciences), Shumei Kato (University of California San Diego) |
| title_full_unstemmed | Therapeutic targeting of RAS mutant cancers Edward C. Stites (Salk Institute for Biological Studies), Kendra Paskvan (Pacific Northwest University for Health Sciences), Shumei Kato (University of California San Diego) |
| title_short | Therapeutic targeting of RAS mutant cancers |
| title_sort | therapeutic targeting of ras mutant cancers |
| topic | Oncology / BIC2 Pathology / BIC2 Pharmacology / BIC2 |
| topic_facet | Oncology / BIC2 Pathology / BIC2 Pharmacology / BIC2 |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=034606755&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT stitesedwardc therapeutictargetingofrasmutantcancers AT paskvankendra therapeutictargetingofrasmutantcancers AT katoshumei therapeutictargetingofrasmutantcancers |